Risk Factors, Screening and Seroprevalence of Dengue Virus Antigen (NS1) in Clinically Suspected Patients: A Community-Based Hospital Study

Abstract

Objectives: The study aims to find out the highly exposed age group, gender, area risk factors and serological marker.

Study Design: Cross sectional

Study Area: The Study was conducted at Civil Hospital from July 2022 to September 2022.

Methodology: All the tests were performed by the AccessBio® kit methodology.

Results: About 945 positive patients were included in the study for diagnosis, of whom 594 were Male and 351 were Female. Fever calculated with p= 0.007, a rapid, weak pulse, pallor or cool skin, rashes calculated like p= 0.005, headache with p= 0.001. We reported following groups 18-30yrs (718, 75.9%), 30-40yrs (103, 10.8%), 40-50yrs (45, 4.76%), and 50-60yrs (79, 8.3%). M=236, SD=278, Variance, σ2= 77785.6 and Cl=95%, 1.960σx̄ 236.25 ±273.323(±115.69%). The affected areas such as (Barradaar 41, 4.3%), (Chouiyan 76, 8.04%), (New Darband 423, 44.7%), (Naryaani 27, 2.87%), (Kajla 52, 5.50%), (Garh-Bala 118, 12.4%), and (Bandi 115, 12.1). M=118.1, SD=119.3, Variance, σ2= 14248.6, Cl=95%, 1.960σx̄ 118.125 ±82.717 (±70.03%), and probability at 0.004. In males, IgG/IgM (27, 4.5%), IgM/NS1 (314, 53.8%), IgG/NS1 (193, 32.4%), and IgM with 60, 10.1%). M=148.5, SD=113.9, Variance, σ2= 12991.25, Cl=95%, 1.960σx̄ 148.5 ±111.7 (±75.22%), and probability was 0.003. In female IgG/IgM (61,017.3%), IgM/NS1 (37, 10.5%), IgG/NS1 (75, 21.3%), and IgM with 178, 50.7%). M=87.7, SD=53.8, Variance, σ2= 2899.68, Cl=95%, 1.960σx̄ 87.75 ±52.772 (±60.14%), and probability was 0.003.

Conclusion: We screened the most affected area such as New Darband, a higher seroprevalence of NS1 was found in males as compared to females and the highly exposed age group was 18-30yrs.